[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-neuropathies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-neuropathies":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,48,76,106,140,174,203,235],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100589812","balance4mobility-effects-of-walkasins-use-in-individuals-with-peripheral-neuropathy-and-balance-problems-100589812",false,"NCT06959277","Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems","Balance4Mobility: Effects of Walkasins Use on Clinical Outcomes of Gait and Balance Function in Individuals With Peripheral Neuropathy and Balance Problems - A Randomized Control Trial","Inclusion Criteria:\n\n* Able to understand and provide informed consent for him or herself\n* Age 55 and older, male or female\n* Able to complete all functional outcome measures without the use of an assistive device\n* Clinical diagnosis of peripheral neuropathy prior to participating in the study as documented in the participant's medical record or by physician's note. Individuals with chemo-induced peripheral neuropathy must be at least one-year post-chemotherapy, indicating that their PN has become a chronic condition.\n* Self-reported gait and balance problems\n* Foot size that allows the Walkasins to function appropriately\n* Willing to use the Walkasins device as recommended\n\nExclusion Criteria:\n\n* Ability to stand on one leg for at least 30 seconds (If the person can stand for at least 30 seconds, he\u002Fshe is excluded because his\u002Fher balance is likely not impaired enough to benefit from Walkasins.)\n* Self-reported acute thrombophlebitis, including deep vein thrombosis\n* Self-reported severe peripheral vascular disease\n* Untreated lymphedema\n* Untreated lesion of any kind, swelling, infection, inflamed area of skin or eruptions on the lower leg near product use\n* Self-reported, untreated fractures in the foot and ankle\n* Other neurological or musculoskeletal conditions that moderately or severely impact walking\n* Use of ankle-foot orthosis for ambulation that prevents donning of Walkasins\n* Weight of more than 300 pounds\n* Inability to perceive vibration from Walkasins Haptic Module","ALL","55 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main question it aims to answer is whether participants who use Walkasins on an everyday basis over a six-month period will report better awareness of their foot placement on the ground.\n\nResearchers will compare Walkasins users to a control group of participants who are not using Walkasins to see if the device improves the users' performance on some standing and walking tests. Control group participants will get Walkasins after six months of being in the study.\n\nDuring the study participants will be asked to do the following:\n\n* Answer questions about their medical history and balance.\n* Do some standing and walking tests. Some of the tests will be timed.\n* Attend study visits and participate in study phone calls.\n* Keep track of any falls and notify study staff if they fall.\n* Wear the Walkasins device on a regular basis.",[26,27,28,29,30],"Peripheral Neuropathies","Peripheral Neuropathy Due to Chemotherapy","Peripheral Neuropathy With Type 2 Diabetes","Balance Control in Elderly","Gait Disorders",[32,33,34],"Walkasins","Peripheral Neuropathy","Balance Problems","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-24","ACTUAL",{"date":41,"type":39},"2025-06-17",{"date":43,"type":20},"2027-12-31",{"name":45,"class":46},"RxFunction Inc.","INDUSTRY",6,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100642645","assessment-of-peripheral-neuropathy-in-ankylosing-spondylitis-100642645","NCT07641920","Assessment of Peripheral Neuropathy in Ankylosing Spondylitis","Assessment of Peripheral Neuropathy in Ankylosing Spondylitis and Its Correlation With, Central Sensitization, Disease Activity and Quality of Life","Inclusion Criteria:\n\n* Patients aged ≥18 years\n* Diagnosis of ankylosing spondylitis according to the modified New York criteria (6).\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Patients under the age of 18 years.\n* Patients with definite diagnosis for any other systemic autoimmune disorders.\n* Diabetes mellitus\n* Chronic renal or hepatic disease\n* Alcohol abuse or drug-induced neuropathy\n* Known neurological disorders affecting peripheral nerves","18 Years",{"count":57,"type":20},45,"OBSERVATIONAL","investigators hypothesized that peripheral neuropathy in ankylosing spondylitis is associated with higher disease activity, greater central sensitization, worse functional impairment, and poorer quality of life.",[61,26],"Ankylosing Spondylitis",[61,63,33],"Quality of Life","NOT_YET_RECRUITING","2026-06-10",{"date":67,"type":39},"2026-06-12",{"date":69,"type":20},"2026-06-30",{"date":71,"type":20},"2026-10-01",{"name":73,"class":74},"Assiut University","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100628170","comparison-of-wrist-splint-positions-in-carpal-tunnel-syndrome-100628170","NCT07458152","Comparison of Wrist Splint Positions in Carpal Tunnel Syndrome","Evaluation of the Effectiveness of Splint Use in Different Wrist Positions in the Treatment of Carpal Tunnel Syndrome: A Single-Blind, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of mild to moderate carpal tunnel syndrome confirmed by electrophysiological studies performed within the last year.\n* Clinical findings consistent with carpal tunnel syndrome.\n* Age between 18 and 65 years.\n\nExclusion Criteria:\n\n* \\\u003C18 years or \\>65 years\n* Thenar atrophy\n* Surgery history for CTS\n* Steroid injection for CTS\n* Physical treatment for CTS in the last 6 months\n* Cervical radiculopathy\n* Tenosynovitis\n* Peripheral polyneuropathy\n* Another compressive neuropathy in the ipsilateral upper extremity\n* History of trauma\u002Ffracture to the hand-wrist region\n* Pregnancy\n* Metabolic disease\n* Rheumatic\u002Fautoimmune disease\n* Kidney failure","65 Years",{"count":85,"type":20},108,[23],"Carpal tunnel syndrome (CTS) is the most common nerve compression syndrome. It develops as a result of the compression of the median nerve while passing through the osteofibrous structure of the carpal tunnel located at the wrist. Sensory symptoms are the most prominent feature of CTS. These symptoms are observed as pain, paresthesia, and decreased sensory sensitivity. As motor symptoms, thumb abduction and opposition are primarily affected. In advanced cases, atrophy develops in the thenar muscles. Patients may describe weakness as difficulty in writing, opening jars, buttoning, or grasping objects. The diagnosis is made by fulfilling both clinical and electrophysiological diagnostic criteria. CTS has both conservative and surgical treatment options. Conservative treatment includes splinting, physical therapy modalities, and injection options, and it is preferred in mild and moderate cases. Among non-surgical treatment options, splint use is a commonly applied intervention; however, there is no consensus regarding its effectiveness, the optimal wrist position during use, or the duration and frequency of splint application. A total of 108 hands from patients aged 18 to 55 years diagnosed with CTS will be included in this study and randomized into three groups. All groups will be given an education and exercise program. The first group will use a wrist splint fixed at 15° flexion; the second group at neutral position; and the third group at 20° extension, to be worn only at night for eight weeks. Patients will be evaluated before treatment, immediately after treatment, and two months after the end of treatment using measures of pain- numbness severity, functional status, motor and sensory examination findings, and nerve conduction studies. What makes this study unique is that it evaluates the effects of splints that stabilize the wrist at different angles together with electrophysiological findings. A review of the literature shows that while some studies have examined and compared the effects of splints fixed at different wrist angles on symptoms, functional status, and physical examination findings, there is no study that evaluates these effects along with electrophysiological findings. Therefore, this study, which will compare the effectiveness of splints at different angles, is expected to contribute to the literature. The expected outcomes of this research are that one or more types of splints used in the conservative treatment of CTS will provide improvements in symptom severity, functional status, sensory and motor physical examination findings, and electrophysiological evaluation findings at the end of treatment.",[89,26,90],"Carpal Tunnel Syndrome (CTS)","Median Nerve Entrapment",[92,93,94,95,96],"Splints","Electromyography","Wrist splinting","Rehabilitation","Wrist posture","2026-03-10",{"date":99,"type":39},"2026-03-12",{"date":101,"type":20},"2026-03",{"date":103,"type":20},"2029-01",{"name":105,"class":74},"Istanbul University",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":75},"100578130","feasibility-testing-of-a-tai-chi-program-for-chemotherapy-induced-peripheral-neuropathy-treatment-tct-100578130","NCT06807294","Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)","Inclusion Criteria:\n\n* Age 18 years old and older\n* Cancer survivors with no evidence of disease (cancer);\n* Completed neurotoxic chemotherapy, i.e., platinum agents, taxanes, vinca alkaloids, and bortezomib, at least three months before enrollment;\n* A CIPN diagnosis based on symptom history, loss of deep tendon reflexes, or presence of symmetrical stocking-glove pain, numbness, or paresthesia;\n* Answers \"yes\" to the following question: \"Do you feel as though your balance is affected from experiencing CIPN?\" or \"Are you afraid of falling as a result of your CIPN?\";\n* On a stable regimen (no change in past three months) if taking anti-neuropathy or other pain medications;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤ 2\n* Willing to adhere to all study-related procedures, including randomization to the Tai Chi or waitlist group, 2 in-person visits to Dana-Farber Cancer Institute (DFCI) (one within 2 weeks of enrollment and one at week 12);\n* Willing to adhere to requirement that no new pain medication be taken throughout the study period; and\n* Individuals receiving endocrine therapy or targeted\u002Fantibody therapy, such as trastuzumab, pertuzumab, or immunotherapy, will be eligible to participate.\n\nExclusion Criteria:\n\n• Patients who have received physical therapy or Tai Chi training, specifically for CIPN, in the past three months.",{"count":113,"type":20},21,[23],"This research is being done to determine whether a 12-week virtual Tai Chi training program, designed to improve balance and small nerve fiber function, is feasible and acceptable among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).",[117,27,26,118],"Chemotherapy Induced Peripheral Neuropathy (CIPN)","Neuropathy",[33,120,121,122,123,124,125,126,127,128,129,130],"Chemotherapy Induced Peripheral Neuropathy","Cancer survivor","CIPN","Tai Chi","Balance training","Falls prevention","Non-pharmacological intervention","Mind-body exercise","Quality of life","Feasibility study","Pilot study","2026-01-27",{"date":133,"type":39},"2026-01-29",{"date":135,"type":39},"2026-01-16",{"date":137,"type":20},"2026-10-31",{"name":139,"class":74},"Dana-Farber Cancer Institute",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":157,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100619236","environmental-factors-associated-with-peripheral-neuropathies-in-french-guiana-100619236","NCT07341997","Environmental Factors Associated With Peripheral Neuropathies in French Guiana","YANANER","Inclusion Criteria:\n\n* For the Case group: patients diagnosed with diabetic peripheral neuropathy or chronic idiopathic axonal polyneuropathy\n* For the Control group: patients hospitalized or consulting at the hospitals in Cayenne and Saint-Laurent du Maroni, without peripheral neuropathy.\n\nExclusion Criteria:\n\n* For the Case and Control groups: patients under the age of 18, those who object to participation and those who are unable to complete the questionnaire.",true,{"count":149,"type":20},78,[23],"Peripheral neuropathies (PN) affect 1% of the global population, particularly the elderly. About 20-30% of cases remain unexplained. In French Guiana, we hypothesize that factors like neurotoxic traditional plant remedies, arboviral disease outbreaks, and mercury exposure from illegal gold mining may contribute to PN. The study aims to assess the association between PN and exposure to arboviral infections, heavy metals, and plant consumption in French Guiana.",[26,153,154,155,156],"Environmental Risk Factor","Lead Neuropathy","Mercury Neuropathy","Bita",[158,159,160,161,162,163],"Preipheral neuropathies","French guiana","Mercury","Lead","Arboviruses","Environment","2026-01-06",{"date":166,"type":39},"2026-01-15",{"date":168,"type":39},"2025-12-08",{"date":170,"type":20},"2027-07",{"name":172,"class":74},"Admin CIC",2,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":147,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100613610","translating-single-cell-vulnerability-into-novel-als-biomarkers-and-therapeutic-targets-towards-a-liquid-nerve-biopsy-100613610","NCT07268833","Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy","TUNEABLE","Inclusion Criteria for als patients:\n\n* Age equal or over 18 years old\n* ALS patients, diagnosed accordingly to the revised El Escorial Criteria\n* Disease duration \\\u003C24 months from symptom onset.\n\nExclusion Criteria for als patients:\n\n* FVC \\\u003C60%;\n* nutritional or respiratory failure;\n* significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.\n\nInclusion criteria for ALS pre-symptomatic patients\n\n* Age equal or over 18 years old\n* Patients with genetic defined susceptibility to ALS and one or more strict relative affected from ALS Exclusion criteria for ALS pre-symptomatic patients\n* significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.\n\nInclusion criteria for controls\n\n* Age equal or over 18 years old\n* Subjects without a diagnosis of neurodegenerative disease or neuromuscular disorder.\n\nExclusion criteria for controls\n\n• significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.\n\nInclusion criteria for non ALS neurodegenerative patients\n\n* Age equal or over 18 years old\n* For AD: Diagnosis according to 2018 NIA-AA Framework for Alzheimer's Disease\n* For FTD: Diagnosis according to 2011 International Behavioural Variant FTD Criteria Consortium\n* For PD: Diagnosis according to 2015 Movement Disorder Society criteria\n* For DLB: Diagnosis according to 2017 Fourth Consensus Report of the DLB Consortium Exclusion criteria for non ALS neurodegenerative patients\n* significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.\n\nInclusion criteria for neuromuscular disease patients\n\n* Age equal or over 18 years old\n* Presence of axonal or demyelinating neuropathy Exclusion criteria for neuromuscular patients\n* significant hepatic or chronic renal failure or any interveninginfective or metabolic conditions potentially influencing CBs levels.",{"count":182,"type":20},400,"The progress of ALS research and clinical practice is hampered by lack of effective biomarkers to monitor disease onset and progression. In response to this urgent need, we will integrate single-cell system biology approaches, histopathological and clinical data from precious human nerve biopsies collected from living ALS patients during the diagnostic workup and findings from innovative preclinical mouse models to unmask cell-specific molecular alterations that arise in the PNS tissue during the course of ALS pathology. This information will be used to select protein biomarkers of dysfunctional states associated with pre-manifest or early symptomatic stages of the disease, which will be further screened and validated in patient biofluids. Altogether, this project will lead to the discovery of novel, reliable and specific ALS biomarkers while providing insights into ALS mechanisms by leveraging an original \"PNS perspective\" on disease pathogenesis.",[185,26],"Amyotrophic Lateral Sclerosis (ALS)",[187,26,188,189,190,191,192,193],"ALS","Motor Neuron Disease","Biomarkers","Neurodegeneration","Nerve Biopsy","skin biopsy","Spatial Transcriptomics","2025-11-25",{"date":168,"type":39},{"date":197,"type":39},"2024-10-24",{"date":199,"type":20},"2027-04",{"name":201,"class":74},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",4,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":210,"targetDuration":212,"studyType":58,"phases":4,"briefSummary":213,"conditions":214,"keywords":221,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":173},"100605729","ultrasound-evaluation-of-hematoma-risk-after-needle-emg-in-patient-on-doac-therapy-100605729","NCT07166302","Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy","U-HAND","Inclusion Criteria:\n\n* Subjects must understand the nature of the study and must provide signed and dated written informed consent prior to conducting any study-related procedures\n* Willing and able to comply with all protocol procedures\n* subjects confirmed the daily (and recent) intake od direct anticoagulants in strandard dosing.\n* no other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is taken.\n\nExclusion Criteria:\n\n* Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject\n* other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is recently taken.",{"count":211,"type":20},70,"7 Days","Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hematomas at the muscles where the EMG needle was inserted. These hematomas are considered a potential adverse effect of needle EMG.\n\nThe aim of the study is to determine whether needle EMG can be considered a safe procedure in this group of patients, without posing a risk of intramuscular hematoma formation.",[215,216,217,26,218,219,220],"Direct Acting Anticoagulant Adverse Reaction","Needle Injury","EMG","Mononeuropathies","Polyneuropathies","Neuromuscular Diseases (NMD)",[222,223,224,225],"electromyography","hematoma","ultrasonography","anticoagulants","2025-09-03",{"date":228,"type":39},"2025-09-10",{"date":230,"type":20},"2025-09",{"date":232,"type":20},"2026-12-31",{"name":234,"class":74},"Masaryk University",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":242,"targetDuration":244,"studyType":58,"phases":4,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":75},"100605265","this-study-aims-to-clarify-the-prevalence-and-characteristics-of-neuropathy-along-with-associated-paraclinical-findings-in-patients-with-waldenstrms-macroglobulinemia-wm-in-a-cohort-of-wm-patients-to-optimize-the-diagnostic-process-100605265","NCT07160270","This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process","Neuropathy in Waldenström's Macroglobulinemia: Pathophysiology, Prognosis and Treatment","Inclusion Criteria:\n\n* Diagnosis of Waldenström's Macroglobulinemia with symptoms of peripheral neuropathy for further clinical investigation.\n\nExclusion Criteria:\n\n* Investigated with no sign of peripheral neuropathy",{"count":243,"type":20},90,"3 Years","Neuropathy severely reduces patients' quality of life due to sensory loss, chronic neuropathic pain, and loss of mobility of arms and legs. Given the diverse origins of neuropathy, it is critical to identify its specific causes, particularly when effective treatments are available. Neuropathy is a frequent morbidity in Waldenström's macroglobulinemia (WM), a specific type of lymphoma caused by infiltration of clonal lymphoplasmocytic B cells in the bone marrow with the presence of IgM paraprotein. WM associated neuropathy is largely undescribed. The few existing studies are mostly retrospective indicating the neuropathy has a heterogenic pathophysiology and diverse clinical appearance from mild sensory neuropathy to aggressive with loss of ambulation and development of chronic neuropathic pain within weeks to months.\n\nWith treatment of WM the speed of the disease progression including the related neuropathy can be halted. Few studies and clinical experience indicate that the nerve damage induced by WM might remit if treatment is initiated early in the course of the disease. Thus, there is need for timely interventions to reduce chronic disabilities. However, even for an experienced neurologist, it can be difficult to identify whether the neuropathy is caused by WM or other causes where treatment is not indicated.\n\nThis project aims to investigate the prevalence and underlying mechanisms of neuropathy in patients with WM to help speed up the diagnostic process and thus help slow down the irreversible nerve damage that these patients experience.",[247,26],"Waldenstrom Macroglobulinaemia","2025-08-29",{"date":250,"type":39},"2025-09-08",{"date":252,"type":39},"2025-05-14",{"date":254,"type":20},"2025-12-30",{"name":256,"class":74},"Rigshospitalet, Denmark"]